"This is co-opting a headline to try to gain political capital, which is really unfortunate," said Shkreli, who has been sent a letter asking him to appear before a Senate committee next month to discuss his company's astronomical price spike.
Shkreli said the price increases by Turing and other companies that are the focus of the Senate investigation are not significantly affecting overall cost trends in the pharmaceutical industry, because "these are small drugs ... tiny drugs," with little market share.
"Given the $500 billion industry ... neither this nor any other pricing increase will change the industry," he said.
Shkreli also said he would make a "modest" decrease to the price of Turing's drug Daraprim, at least for some customers, by the end of this year. Daraprim is used to treat a parasitic condition known as toxoplasmosis, which is seen in HIV patients and pregnant women.
He previously has promised, after facing criticism, that he would cut Daraprim's retail price. But that hasn't happened yet.
"I haven't decided it to be 10 [percent] or 5 or 20 percent or anything yet, but it'll be modest," Shkreli said Wednesday. Those price cuts will be for customers covered by private and government-run insurance.